Rechercher
image du produit
Lancet Oncology, The

S'abonner

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial - 02/09/25

Doi : 10.1016/S1470-2045(25)00339-0 
Louise Emmett, ProfMD a, c, d, ⁎ , Nathan Papa, PhD d, Shalini Subramaniam, MBBS e, f, Megan Crumbaker, PhD b, c, d, Andrew Nguyen, MBBS a, c, Anthony M Joshua, ProfPhD b, c, d, Shahneen Sandhu, ProfMBBS g, Andrew Weickhardt, PhD i, k, Sze-Ting Lee, ProfPhD j, k, l, Siobhan Ng, MBBS m, Roslyn J Francis, PhD n, o, Jeffrey C Goh, ProfMBBS p, r, David A Pattison, MBBS q, s, Thean Hsiang Tan, MBBS u, Ian D Kirkwood, MBBS v, w, Narjess Ayati, MBBS a, c, d, Claire Niu, MSc e, Michael S Hofman, ProfMBBS g, x, Andrew James Martin, ProfPhD e, h, t, Hayley Thomas, MBiostat e, Ian D Davis, ProfPhD y, z, aa, *, Martin R Stockler, ProfMBBS e, ab, *
for the

ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group †

  All ENZA-p trial collaborators are listed in the appendix (pp 20–21)
Louise Emmett, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M. Joshua, Shahneen Sandhu, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Maddison Bills, Jasmine Brady, Ian D. Kirkwood, Narjess Ayati, Claire Niu, Michael S. Hofman, Andrew J. Martin, Hayley Thomas, Ian D. Davis, Martin R. Stockler, Nicole Tankard, Samantha Oakes, Alison Y Zhang, Jennifer Thompson, Thida Thein, Thomas Cusick, Shikha Sharma

a Department of Theranostics and Nuclear Medicine, St Vincent’s Hospital, Sydney, NSW, Australia 
b Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent’s Hospital, Sydney, NSW, Australia 
c St Vincent’s Clinical School, University of New South Wales, Sydney, NSW, Australia 
d Garvan Institute of Medical Research, Sydney, NSW, Australia 
e NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia 
f Department of Medical Oncology, Bankstown-Lidcombe Hospital, Sydney, NSW, Australia 
g Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia 
h ULTRA The University of Queensland Clinical Trials Capability, Centre for Clinical Research, Brisbane, QLD, Australia 
i Olivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, VIC, Australia 
j Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia 
k School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia 
l Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia 
m Department of Oncology, Sir Charles Gairdner Hospital and University of Western Australia, Perth, WA, Australia 
n Department of Nuclear Medicine, Sir Charles Gairdner Hospital and University of Western Australia, Perth, WA, Australia 
o Medical School, University of Western Australia, Perth, WA, Australia 
p Department of Oncology, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia 
q Department of Nuclear Medicine and Specialised PET Services, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia 
r Queensland University of Technology, Brisbane, QLD, Australia 
s School of Medicine, University of Queensland, Brisbane, QLD, Australia 
t Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia 
u Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia 
v Nuclear Medicine, PET and Bone Densitometry, Royal Adelaide Hospital, Adelaide, SA, Australia 
w Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia 
x Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) and Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 
y Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Sydney, NSW, Australia 
z Monash University Eastern Health Clinical School, Melbourne, Australia 
aa Eastern Health, Melbourne, VIC, Australia 
ab Department of Medical Oncology, Chris O’Brien Lifehouse, Sydney, NSW, Australia 

* Correspondence to: Prof Louise Emmett, Department of Theranostics and Nuclear Medicine, St Vincent’s Hospital, Sydney, NSW 2010, Australia Department of Theranostics and Nuclear Medicine St Vincent’s Hospital Sydney NSW 2010 Australia

Summary

Background

Quantitative parameters derived from gallium-68 [ 68 Ga]Ga-prostate-specific membrane antigen (PSMA)-11 PET-CT (PSMA-PET-CT) such as whole-body standardised uptake value (SUV)mean and total tumour volume (PSMA-TTV) have shown prognostic value for response to lutetium-177 [ 177 Lu]Lu-PSMA-617 monotherapy in patients with prostate cancer. Adding [ 177 Lu]Lu-PSMA-617 to enzalutamide improved overall survival compared with enzalutamide in patients with metastatic castration-resistant prostate cancer in the ENZA-p trial. This prespecified substudy of ENZA-p evaluated baseline PSMA-PET quantitative parameters as predictive and prognostic biomarkers for enzalutamide plus [ 177 Lu]Lu-PSMA-617 and enzalutamide monotherapy.

Methods

ENZA-p was an open-label, randomised, phase 2 trial done in 15 hospitals in Australia. Participants were aged 18 years or older with progressive metastatic castration-resistant prostate cancer who had not previously been treated with docetaxel or androgen receptor pathway inhibitors (abiraterone permitted) for metastatic castration-resistant prostate cancer, had [ 68 Ga]Ga PSMA-PET-CT-positive disease, an Eastern Cooperative Oncology Group performance status of 0–2, and at least two risk factors for early progression on enzalutamide. Patients were randomly assigned (1:1) by a centralised, web-based system using minimisation with a random component to either enzalutamide 160 mg daily (oral) or enzalutamide 160 mg daily plus adaptive-dosed (two or four doses) intravenous [ 177 Lu]Lu-PSMA-617 7·5 GBq every 6–8 weeks. The primary endpoint was prostate-specific antigen (PSA) progression-free survival, which has been reported previously. All participants underwent baseline [ 68 Ga]Ga-PSMA-11 PET-CT to assess eligibility (SUVmax > 15 at a single site and SUVmax > 10 at all larger tumour sites). PSMA-PET parameters were quantified with semi-automated software to derive PSMA-TTV and SUVmean and correlated with overall and PSA progression-free survival in a prespecified analysis, with the primary endpoint of this substudy being overall survival. Thresholds were based on SUVmean highest quartile (Q4 vs Q1–3) and PSMA-TTV median at baseline. We used the Kaplan–Meier method and Cox regression models and analysed patients on a treatment received basis. The trial is registered with ClinicalTrials.gov, NCT04419402, and follow-up is complete.

Findings

Between Aug 17, 2020, and July 26, 2022, 162 participants were randomly assigned to enzalutamide (n=79) or enzalutamide plus [ 177 Lu]Lu-PSMA-617 (n=83). This substudy included the 160 of the 162 randomly assigned patients who received study treatment (79 in the enzalutamide group and 81 in the enzalutamide plus [ 177 Lu]Lu-PSMA-617 group). Median follow-up at the final data cutoff (July 31, 2024) was 34 months (IQR 29–39), with 96 overall survival events (53 with enzalutamide and 43 with enzalutamide plus [ 177 Lu]Lu-PSMA-617). Baseline median SUVmean was 7·7 (IQR 6·5–9·8) and median PSMA-TTV was 234 mL (76–687). Median overall survival for PSMA-TTV below or above the median in the enzalutamide group was 39 months (95% CI 31–not estimable) versus 20 months (13–24; HR 0·23 [95% CI 0·13–0·42], log-rank p < 0·0001). The corresponding median overall survival for PSMA-TTV below or above the median in the enzalutamide plus [ 177 Lu]Lu-PSMA-617 group was 35 months (95% CI 32–37) versus 28 months (26–34; HR 0·66 [0·36–1·21], log-rank p=0·18). The test for interaction between PSMA-TTV and treatment group for overall survival was p=0·0078. Median overall survival for SUVmean Q4 versus Q1–3 in the enzalutamide group was 29 months (95% CI 17–39) versus 25 months (21–31; HR 0·84 [0·44–1·60], log-rank p=0·59). For enzalutamide plus [ 177 Lu]Lu-PSMA-617, median overall survival for SUVmean Q4 versus Q1–3 was 32 months (95% CI 21–not estimable) versus 34 months (27–35; HR 0·80 [0·38–1·68], log-rank p=0·56). The test for interaction between SUVmean (Q4 vs Q1–3) and treatment group for overall survival was p=0·88.

Interpretation

Baseline PSMA-TTV is prognostic for overall survival and predictive for a beneficial effect on overall survival with the addition of [ 177 Lu]Lu-PSMA-617 to enzalutamide as first-line treatment for high-risk metastatic castration-resistant prostate cancer. By contrast, PSMA SUVmean was not prognostic for PSA progression-free survival or overall survival when [ 177 Lu]Lu-PSMA-617 was administered with enzalutamide.

Funding

The Prostate Cancer Research Alliance initiative (Movember and Australian Federal Government), Prostate Cancer Foundation Challenge Award, St Vincent’s Clinic Foundation, GenesisCare, RoyMorgan, Endocyte (a Novartis company), and Astellas.

Le texte complet de cet article est disponible en PDF.

Plan


© 2025  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

    •

  • Contenu

    •

Vol 26 - N° 9

P. 1168-1177 - septembre 2025 Retour au numéro
Article précédent Article précédent
  • Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial
  • Tamim Niazi, Fred Saad, Steven Tisseverasinghe, Rashmi Koul, Isabelle Thibault, Peter W M Chung, George Wakil, Michael Lock, Guila Delouya, Boris Bahoric, Andrew Feifer, Venkata Ramana Agnihotram, Theodoros Tsakiridis, Fabio L Cury, Rafika Dahmane, Nikhilesh Gajanan Patil, Scott Tyldesley
| Article suivant Article suivant
  • The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis
  • Karenna J Groff, Ruchit V Patel, Yang Feng, Hia S Ghosh, Miguel A Millares Chavez, Joseph O’Brien, William C Chen, Vijay Nitturi, Akshay V Save, Mark W Youngblood, Craig M Horbinski, James P Chandler, Felix Ehret, Chloe Gui, Justin Z Wang, Kristen Park, Sonia Ajmera, Marc Rosenblum, Abigail K Suwala, Catena Kresbach, Christopher W Mount, Ulrich Schüller, Sandro Santagata, Felix Sahm, Tejus A Bale, Christina Jackson, Timothy E Richardson, Chunyu Cai, Farshad Nassiri, Gelareh Zadeh, David Kaul, David Capper, Stephen T Magill, John G Golfinos, Chandra Sen, Akash J Patel, David R Raleigh, Jennifer Moliterno, Donato Pacione, Matija Snuderl, Wenya Linda Bi

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.

Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.